Key points: Rituximab added to ibrutinib in relapsed and treatment-naive high-risk patients with CLL failed to show improvement in progression-free survival. Patients treated with ibrutinib plus rituximab reached their remissions faster and achieved significantly lower residual disease levels.
Home / Resource Library / Randomized trial of ibrutinib vs ibrutinib plus rituximab in patients with chronic lymphocytic leukemia